AU6989800A - Diamino-1,2,4-triazole-carboxylic and derivatives as gsk-3 inhibitors - Google Patents

Diamino-1,2,4-triazole-carboxylic and derivatives as gsk-3 inhibitors

Info

Publication number
AU6989800A
AU6989800A AU69898/00A AU6989800A AU6989800A AU 6989800 A AU6989800 A AU 6989800A AU 69898/00 A AU69898/00 A AU 69898/00A AU 6989800 A AU6989800 A AU 6989800A AU 6989800 A AU6989800 A AU 6989800A
Authority
AU
Australia
Prior art keywords
gsk
diamino
triazole
inhibitors
carboxylic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU69898/00A
Inventor
David Glynn Smith
Robert William Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of AU6989800A publication Critical patent/AU6989800A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU69898/00A 1999-08-02 2000-07-31 Diamino-1,2,4-triazole-carboxylic and derivatives as gsk-3 inhibitors Abandoned AU6989800A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9918180.2A GB9918180D0 (en) 1999-08-02 1999-08-02 Novel compositions
GB9918180 1999-08-02
PCT/EP2000/007423 WO2001009106A1 (en) 1999-08-02 2000-07-31 Diamino-1,2,4-triazole-carboxylic and derivatives as gsk-3 inhibitors

Publications (1)

Publication Number Publication Date
AU6989800A true AU6989800A (en) 2001-02-19

Family

ID=10858425

Family Applications (1)

Application Number Title Priority Date Filing Date
AU69898/00A Abandoned AU6989800A (en) 1999-08-02 2000-07-31 Diamino-1,2,4-triazole-carboxylic and derivatives as gsk-3 inhibitors

Country Status (5)

Country Link
EP (1) EP1200415A1 (en)
JP (1) JP2003506362A (en)
AU (1) AU6989800A (en)
GB (1) GB9918180D0 (en)
WO (1) WO2001009106A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100358867C (en) 2000-05-11 2008-01-02 科学研究高等机关 Heterocyclic inhibitors of glycogen synthase kinase GSK-3
ES2166328B1 (en) * 2000-05-11 2003-09-16 Consejo Superior Investigacion HETEROCICLIC INHIBITORS OF ENZYME GSK 3 USEFUL IN THE TREATMENT OF NEURODEGENERATIVE AND HYPERPROLIFERATIVE PROCESSES
EP1712550A3 (en) * 2000-12-22 2009-07-15 Ortho-McNeil Pharmaceutical, Inc. Substituted triazole diamine derivatives as kinase inhibitors
PL363316A1 (en) * 2000-12-22 2004-11-15 Ortho Mc Neil Pharmaceutical, Inc. Substituted triazole diamine derivatives as kinase inhibitors
GB0103031D0 (en) * 2001-02-07 2001-03-21 Smithkline Beecham Plc Novel treatment
CA2455753A1 (en) * 2001-08-03 2003-02-13 Novo Nordisk A/S Novel 2,4-diaminothiazole derivatives
TWI335221B (en) 2001-09-27 2011-01-01 Alcon Inc Inhibtors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma
US20160106717A1 (en) 2004-09-24 2016-04-21 Gen Pharma Holdings LLC Cai-based systems and methods for the localized treatment of uveitis
NZ554686A (en) * 2004-09-24 2011-06-30 Rfe Pharma Llc Cai-based systems and methods for the localized treatment of ocular and other diseases
EP1797049A4 (en) 2004-10-08 2009-06-17 Janssen Pharmaceutica Nv 1,2,4-triazolylaminoaryl (heteroaryl) sulfonamide derivatives
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
WO2007025177A2 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
WO2007030680A2 (en) * 2005-09-07 2007-03-15 Rigel Pharmaceuticals, Inc. Triazole derivatives useful as axl inhibitors
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536669A (en) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド Neurogenesis by angiotensin regulation
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2484679B1 (en) 2006-12-29 2016-09-28 Rigel Pharmaceuticals, Inc. N3-heteroaryl substituted triazoles and n5-heteroaryl substitued triazoles useful as axl inhibitors
EP2114954B1 (en) 2006-12-29 2013-02-13 Rigel Pharmaceuticals, Inc. Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors
ES2656496T3 (en) 2006-12-29 2018-02-27 Rigel Pharmaceuticals, Inc. Substituted triazoles useful as AXL inhibitors
WO2008083357A1 (en) 2006-12-29 2008-07-10 Rigel Pharmaceuticals, Inc. Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
PL2078010T3 (en) 2006-12-29 2014-07-31 Rigel Pharmaceuticals Inc Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
EP2205592B1 (en) 2007-10-26 2013-05-08 Rigel Pharmaceuticals, Inc. Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors
JP5613156B2 (en) 2008-07-09 2014-10-22 ライジェル ファーマシューティカルズ， インコーポレイテッド Bridged bicyclic heteroaryl substituted triazoles useful as AXL inhibitors
EP2326641B1 (en) 2008-07-09 2014-09-03 Rigel Pharmaceuticals, Inc. Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
RU2555326C2 (en) 2009-01-16 2015-07-10 Риджел Фармасьютикалз, Инк. Axl INHIBITORS APPLICABLE IN COMBINATION THERAPY FOR PREVENTING, RELIEVING OR TREATING METASTATIC CANCER
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20140010783A1 (en) * 2012-07-06 2014-01-09 Hoffmann-La Roche Inc. Antiviral compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2352944A (en) * 1942-07-04 1944-07-04 Gen Electric Triazole derivatives
FI850994L (en) * 1984-03-16 1985-09-17 Ciba Geigy Ag FOERFARANDE FOER FRAMSTAELLNING AV NYA 1,2,4-TRIAZACYKLOALKADIENDERIVAT.
US6599910B1 (en) * 1998-08-20 2003-07-29 Smithkline Beecham Corporation Substituted triazole compounds

Also Published As

Publication number Publication date
EP1200415A1 (en) 2002-05-02
WO2001009106A1 (en) 2001-02-08
JP2003506362A (en) 2003-02-18
GB9918180D0 (en) 1999-10-06

Similar Documents

Publication Publication Date Title
AU6989800A (en) Diamino-1,2,4-triazole-carboxylic and derivatives as gsk-3 inhibitors
AU6314900A (en) Biarylurea derivatives
AU6714700A (en) Cyclopropylindole derivatives
HK1047743A1 (en) New use and novel n-azabicyclo-amide derivatives.
ZA200203003B (en) N-substituted carbamoyloxyalkyl-azolium derivatives.
AU1597201A (en) Pyrrolecarbonylimino derivatives as naaladase inhibitors
AU4579500A (en) Small electronic articles for personal use
AU3819200A (en) 2,4-diamino-pyrimidine derivatives
AU5429000A (en) Novel bicyclonucleoside derivatives
AU7952800A (en) 2-alkoxybenzene derivatives
AU3670000A (en) Novel thiazolobenzimidazole derivatives
GB0023323D0 (en) Arylhydantoin derivatives and uses thereof
AU4315700A (en) N-substituted dihydropyrrole derivatives
AU2002216650A1 (en) Triazine derivatives as lpaat-b inhibitors and uses thereof
PL353214A1 (en) Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-ones and their use as lipase inhibitors
AU3761400A (en) Amino-thio-acrylonitriles as mek inhibitors
AU3235100A (en) Prothease inhibitors
AU7963300A (en) Novel bipyridyl derivatives
AU3883800A (en) Hob-bp2h compositions, methods and uses thereof
AU2002218400A1 (en) 3-substituted 2,7-naphthyridin-1-yl derivatives
AU2002338989A1 (en) Substituted C-furan-2-yl-methylamine and C-thiophen-2-yl-methylamine derivatives
AU1487599A (en) 1,3,4-thiadiazoles derivatives as kyn-oh inhibitors
AU6088799A (en) Substituted thiadiazolsulfonamides used as interleukin-1-beta inhibitors
AU6262300A (en) Indolinylamide derivatives
AU1558300A (en) 1-cycloalkylpyrazoyl-benzoyl derivatives

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase